Lung cancer treatment potential and limits associated with the STAT family of transcription factors
Cellular Signalling · 2023
DOI: 10.1016/j.cellsig.2023.110797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2023. Verfasst von Paison Faida und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Eng…. Hauptthemen laut MEDLINE: Signal Transduction, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 274 Literaturangaben.
Abstract (Originalsprache)
Lung cancer is one of the mortal cancers and the leading cause of cancer-related mortality, with a cancer survival rate of fewer than 5% in developing nations. This low survival rate can be linked to things like late-stage detection, quick postoperative recurrences in patients receiving therapy, and chemoresistance developing against various lung cancer treatments. Signal transducer and activator of transcription (STAT) family of transcription factors are involved in lung cancer cell proliferation, metastasis, immunological control, and treatment resistance. By interacting with specific DNA sequences, STAT proteins trigger the production of particular genes, which in turn result in adaptive and incredibly specific biological responses. In the human genome, seven STAT proteins have been discovered (STAT1 to STAT6, including STAT5a and STAT5b). Many external signaling proteins can activate unphosphorylated STATs (uSTATs), which are found inactively in the cytoplasm. When STAT proteins are activated, they can increase the transcription of several target genes, which leads to unchecked cellular proliferation, anti-apoptotic reactions, and angiogenesis. The effects of STAT transcription factors on lung cancer are variable; some are either pro- or anti-tumorigenic, while others maintain dual, context-dependent activities. Here, we give a succinct summary of the various functions that each member of the STAT family plays in lung cancer and go into more detail about the advantages and disadvantages of pharmacologically targeting STAT proteins and their upstream activators in the context of lung cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Taibai North Road 229, Xi'an, Shaanxi…
- Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
- College of Food Science and Technology, Northwest University, Xi'an, Shaanxi 710069, China.
Zitieren
APA
Faida, P., Attiogbe, M. K. I., Majeed, U., Zhao, J., Qu, L., & Fan, D. (2023). Lung cancer treatment potential and limits associated with the STAT family of transcription factors. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2023.110797
Vancouver
Faida P, Attiogbe MKI, Majeed U, Zhao J, Qu L, Fan D. Lung cancer treatment potential and limits associated with the STAT family of transcription factors. Cellular Signalling. 2023. doi:10.1016/j.cellsig.2023.110797
BibTeX
@article{Faida2023,
author = {Faida, Paison and Attiogbe, Mawusse K I and Majeed, Usman and Zhao, Jing and Qu, Linlin and Fan, Daidi},
title = {Lung cancer treatment potential and limits associated with the STAT family of transcription factors},
journal = {Cellular Signalling},
year = {2023},
doi = {10.1016/j.cellsig.2023.110797}
}
EUVIMED